Application of PCSK9 inhibitors in practice: Challenges and opportunities

Research output: Contribution to journalReview article

11 Citations (Scopus)

Abstract

Although the discovery of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and development of therapeutic antagonists represent a major triumph of modern clinical medicine, efforts to implement PCSK9 inhibitors (PCSK9i) in patient care have been sobering. This practical guide examines the barriers and opportunities for the successful application of pharmacological inhibition of PCSK9 in clinical practice through introduction of a new model of care delivery-the PCSK9i clinic.

Original languageEnglish (US)
Pages (from-to)499-501
Number of pages3
JournalCirculation Research
Volume121
Issue number5
DOIs
StatePublished - Aug 1 2017

Fingerprint

Modern 1601-history
Clinical Medicine
Patient Care
Pharmacology
Proprotein Convertase 9
Therapeutics

Keywords

  • Angina
  • Cholesterol
  • Health
  • Insurance
  • LDL
  • Patient care
  • Secondary prevention
  • Unstable

ASJC Scopus subject areas

  • Physiology
  • Cardiology and Cardiovascular Medicine

Cite this

@article{cd3c97c039464abd994c77cf3d9551f7,
title = "Application of PCSK9 inhibitors in practice: Challenges and opportunities",
abstract = "Although the discovery of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and development of therapeutic antagonists represent a major triumph of modern clinical medicine, efforts to implement PCSK9 inhibitors (PCSK9i) in patient care have been sobering. This practical guide examines the barriers and opportunities for the successful application of pharmacological inhibition of PCSK9 in clinical practice through introduction of a new model of care delivery-the PCSK9i clinic.",
keywords = "Angina, Cholesterol, Health, Insurance, LDL, Patient care, Secondary prevention, Unstable",
author = "Tina Kaufman and Paul Duell and Jonathan Purnell and Cezary Wojcik and Sergio Fazio and Michael Shapiro",
year = "2017",
month = "8",
day = "1",
doi = "10.1161/CIRCRESAHA.117.311532",
language = "English (US)",
volume = "121",
pages = "499--501",
journal = "Circulation Research",
issn = "0009-7330",
publisher = "Lippincott Williams and Wilkins",
number = "5",

}

TY - JOUR

T1 - Application of PCSK9 inhibitors in practice

T2 - Challenges and opportunities

AU - Kaufman, Tina

AU - Duell, Paul

AU - Purnell, Jonathan

AU - Wojcik, Cezary

AU - Fazio, Sergio

AU - Shapiro, Michael

PY - 2017/8/1

Y1 - 2017/8/1

N2 - Although the discovery of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and development of therapeutic antagonists represent a major triumph of modern clinical medicine, efforts to implement PCSK9 inhibitors (PCSK9i) in patient care have been sobering. This practical guide examines the barriers and opportunities for the successful application of pharmacological inhibition of PCSK9 in clinical practice through introduction of a new model of care delivery-the PCSK9i clinic.

AB - Although the discovery of proprotein convertase subtilisin/ kexin type 9 (PCSK9) and development of therapeutic antagonists represent a major triumph of modern clinical medicine, efforts to implement PCSK9 inhibitors (PCSK9i) in patient care have been sobering. This practical guide examines the barriers and opportunities for the successful application of pharmacological inhibition of PCSK9 in clinical practice through introduction of a new model of care delivery-the PCSK9i clinic.

KW - Angina

KW - Cholesterol

KW - Health

KW - Insurance

KW - LDL

KW - Patient care

KW - Secondary prevention

KW - Unstable

UR - http://www.scopus.com/inward/record.url?scp=85031006112&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85031006112&partnerID=8YFLogxK

U2 - 10.1161/CIRCRESAHA.117.311532

DO - 10.1161/CIRCRESAHA.117.311532

M3 - Review article

C2 - 28819040

AN - SCOPUS:85031006112

VL - 121

SP - 499

EP - 501

JO - Circulation Research

JF - Circulation Research

SN - 0009-7330

IS - 5

ER -